TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Brii Biosciences Limited ( (HK:2137) ) is now available.
Brii Biosciences Limited announced a supplemental update to its 2024 Annual Report, detailing changes in the use of net proceeds from its global offering. The company has revised its allocation of funds, particularly for its hepatitis B and HIV programs, to better support ongoing clinical trials and regulatory preparations. This strategic reallocation aims to enhance the company’s operational efficiency and strengthen its position in the biotechnology industry.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company incorporated in the Cayman Islands, focusing on developing innovative therapies for infectious diseases such as hepatitis B and HIV. The company is listed on the Hong Kong Stock Exchange and is engaged in clinical trials and preparation for regulatory filings to advance its therapeutic programs.
Average Trading Volume: 6,354,816
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.42B
For detailed information about 2137 stock, go to TipRanks’ Stock Analysis page.